US Patent

US12233049 — Stable pharmaceutical compositions of clonidine

Formulation · Assigned to Slayback Pharma LLC · Expires 2042-07-15 · 16y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable liquid pharmaceutical compositions of clonidine or its salts for oral administration.

USPTO Abstract

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

Drugs covered by this patent

Patent Metadata

Patent number
US12233049
Jurisdiction
US
Classification
Formulation
Expires
2042-07-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Slayback Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.